Screener
Mirum Pharmaceuticals, Inc. MIRM Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Prepaid expenses and other current assets | 26,890 | 18,140 |
| Total current assets | 636,310 | 549,684 |
| Restricted cash | 1,734 | 1,482 |
| Long-term investments | 123,030 | 8,105 |
| Property and equipment, net | 2,251 | 1,862 |
| Operating lease right-of-use assets | 12,024 | 8,741 |
| Intangible assets, net | 247,388 | 260,921 |
| Other assets | 22,244 | 12,018 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s equity method investments?
- Mirum Pharmaceuticals, Inc. (MIRM) reported equity method investments of $123.03M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s equity method investments changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s equity method investments increased by 619.0% year-over-year, from $17.11M to $123.03M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Mirum Pharmaceuticals, Inc.'s equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude